ADMA (STOCKS)
ADMA Biologics, Inc.
$9.410000
-0.370000 (-3.78%)
Prev close: $9.780000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Adam S. Grossman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,361.00M
- Employees
- 685
- P/E (TTM)
- 13.88
- P/B (TTM)
- 5.40
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
7
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$0.16 | $0.18 | -0.0160 | -9.09% |
|
Mar 2026 (Q1)
|
$0.19 | $0.20 | -0.0140 | -6.86% |
|
Dec 2025 (Q4)
|
$0.20 | $0.19 | +0.0113 | +5.99% |
|
Sep 2025 (Q3)
|
$0.15 | $0.15 | -0.0030 | -1.96% |
Financial Statements
| Revenues | $512.28M |
| Benefits Costs and Expenses | $295.80M |
| Cost Of Revenue | $180.81M |
| Costs And Expenses | $295.80M |
| Gross Profit | $331.47M |
| Nonoperating Income/Loss | -$8.01M |
| Operating Expenses | $106.99M |
| Selling, General, and Administrative Expenses | $98.77M |
| Depreciation and Amortization | $7.69M |
| Research and Development | $11.52M |
| Operating Income/Loss | $224.48M |
| Income/Loss From Continuing Operations After Tax | $168.96M |
| Income/Loss From Continuing Operations Before Tax | $216.47M |
| Income Tax Expense/Benefit | $47.52M |
| Income Tax Expense/Benefit, Deferred | $9.27M |
| Net Income/Loss | $168.96M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $168.96M |
| Net Income/Loss Available To Common Stockholders, Basic | $168.96M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.72 |
| Diluted Earnings Per Share | $0.70 |
| Basic Average Shares | 702,799,214 |
| Diluted Average Shares | 714,370,379 |
| Assets | $684.21M |
| Current Assets | $528.20M |
| Inventory | $239.31M |
| Other Current Assets | $288.89M |
| Noncurrent Assets | $156.01M |
| Fixed Assets | $66.66M |
| Intangible Assets | $575.00K |
| Other Non-current Assets | $88.77M |
| Liabilities | $276.00M |
| Current Liabilities | $75.76M |
| Accounts Payable | $31.72M |
| Other Current Liabilities | $44.03M |
| Noncurrent Liabilities | $200.25M |
| Long-term Debt | $196.59M |
| Other Non-current Liabilities | $3.66M |
| Equity | $408.21M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $408.21M |
| Liabilities And Equity | $684.21M |
| Net Cash Flow From Operating Activities | $136.72M |
| Net Cash Flow From Operating Activities, Continuing | $136.72M |
| Net Cash Flow From Investing Activities | -$14.50M |
| Net Cash Flow From Investing Activities, Continuing | -$14.50M |
| Net Cash Flow From Financing Activities | -$76.49M |
| Net Cash Flow From Financing Activities, Continuing | -$76.49M |
| Net Cash Flow | $45.74M |
| Net Cash Flow, Continuing | $45.74M |
| Comprehensive Income/Loss | $168.96M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $168.96M |
| Other Comprehensive Income/Loss | $0.00 |